ABB
NYSE · Industrials
ABB Ltd
—
(—)
ABB News17 articles
HCLTech Plunge Triggers IT Rout, Drags Sensex and Nifty Lower
Indian equity benchmarks snapped a three-day winning streak as HCLTech's disappointing growth forecast triggered a sharp selloff in IT stocks, with the Nifty 50 closing below 24,500.
NVIDIA, ABB Forge Factory AI Alliance to Bridge Simulation-Reality Gap
NVIDIA and ABB have announced a strategic partnership to embed NVIDIA's Omniverse platform into ABB's RobotStudio software, aiming to achieve near-perfect accuracy when transferring robot training from simulation to physical factories. The collaboration is a key move for NVIDIA to expand its industrial AI footprint beyond data centers.
GE Vernova Shares Slide 5% Amid Broad Market Sell-Off
GE Vernova shares declined approximately 5% on Tuesday, underperforming a broader market downturn. The power equipment firm detailed a $30 million expansion in Italy and finalized the sale of its Proficy software unit.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
AbbVie Stock Gains on Positive Pipeline Updates Ahead of Holiday
AbbVie closed Friday at $215.70, up 0.56%, after receiving a positive EU panel recommendation for MAVIRET in acute hepatitis C and releasing new oncology data ahead of ASCO.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.
AbbVie Gains on $8 Billion Bond Sale, Outperforms Slumping Market
AbbVie shares climbed 3.29% to $232.08 on Friday, defying a broader market decline. The pharmaceutical giant is set to raise approximately $7.95 billion through a seven-part bond sale settling March 4.
AbbVie's $1.73 Dividend Payout Arrives Amid Regulatory and Market Headwinds
AbbVie shares gained 1.8% to close at $231.50 Friday ahead of a $1.73 per share dividend payment on Tuesday. The company faces regulatory challenges and competitive pressures despite solid quarterly revenue.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
AbbVie Gains as Analyst Target Hike Meets Macroeconomic Caution
AbbVie shares advanced Tuesday after BNP Paribas Exane raised its price target, while broader markets were mixed as traders awaited delayed U.S. jobs and inflation data.
Abbott Shares Gain on Insider Purchase and Positive Cardiac Device Data
Abbott Laboratories stock rose 1.6% Friday following a director's $1.09 million share purchase and new clinical data for its heart rhythm devices presented at a medical symposium.
AbbVie Gains on Moody's Credit Upgrade, Focus Shifts to Immunology Portfolio
AbbVie shares rose 2% to $223.43 after Moody's upgraded its credit rating to A2 with a stable outlook. Investors now watch demand and pricing for Skyrizi and Rinvoq amid Humira competition.
Abbott Faces Regulatory Scrutiny on Libre Sensors as Insider Buying and New AFib Data Emerge
Abbott shares rose 1.6% to $110.83 Friday but remain 21.5% below their 52-week high. The FDA updated a Class I recall for FreeStyle Libre 3 sensors, citing 860 serious injuries and seven deaths, while an insider purchased 10,000 shares.
AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade
AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.